The startup develops proprietary cancer therapeutics that function as pathway inhibitors, targeting specific mutations in cancer cells to prevent their uncontrolled proliferation. This approach enables oncologists to provide personalized treatment options for patients with tumors exhibiting critical DNA abnormalities linked to cancer progression.
Funding
$310K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers are driven by uncontrolled cell proliferation resulting from DNA abnormalities (mutations) in key signaling pathways. Current cancer treatments often lack specificity, leading to off-target effects and limited efficacy in patients with tumors exhibiting specific driver mutations.
Solution
Anastasis Biotec is developing pathway inhibitors designed to target specific mutations driving cancer cell growth. Their approach involves analyzing tumor biopsies to identify critical mutations, selecting patients whose tumors exhibit these mutations, and treating them with a matching pathway inhibitor. This personalized treatment strategy aims to selectively inhibit the rogue signaling pathways, potentially providing a more effective and less toxic approach to cancer therapy. The company has several pathway inhibitors ready for development.
Target Audience
The primary target audience includes oncologists seeking personalized treatment options for cancer patients with tumors exhibiting specific, targetable mutations, as well as cancer patients who have been identified as having these mutations.
Features
- Targeted therapy approach focusing on specific cancer-driving mutations.
- Diagnostic testing to identify patients with tumors expressing critical mutations.
- Development of pathway inhibitors designed to block the activity of mutated signaling pathways.
- Pre-clinical and clinical trials to evaluate the safety and efficacy of the pathway inhibitors.
- Focus on cancer types with significant unmet clinical needs.